Beyond Antibiotics: Novel Approaches in the Treatment of Recurrent Infection.
作者信息
Zaidi Syed Murtaza Haider, Haider Ramsha, Kazmi Syeda Amna Batool, Husnain Ali, Khan Saniah, Merchant Sabrina, Tayyab Hamnah, Wazeen Fazl Rahim, Chaudhary Ammad Javaid
机构信息
Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Karachi Medical and Dental College, Karachi, Pakistan.
出版信息
ACG Case Rep J. 2024 Jul 27;11(8):e01333. doi: 10.14309/crj.0000000000001333. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Beyond Antibiotics: Novel Approaches in the Treatment of Recurrent Infection.超越抗生素：复发性感染治疗的新方法
ACG Case Rep J. 2024 Jul 27;11(8):e01333. doi: 10.14309/crj.0000000000001333. eCollection 2024 Aug.
2
The role of the gut microbiome in colonization resistance and recurrent infection.肠道微生物群在定植抗性和反复感染中的作用。
Therap Adv Gastroenterol. 2022 Nov 18;15:17562848221134396. doi: 10.1177/17562848221134396. eCollection 2022.
3
Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.稀释粪菌移植可恢复抗生素扰乱的小鼠群落中艰难梭菌的定植抗性。
mBio. 2022 Aug 30;13(4):e0136422. doi: 10.1128/mbio.01364-22. Epub 2022 Aug 1.
4
Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Infection in Rural Hospitals?粪便微生物移植在农村医院治疗复发性感染中的作用？
Front Public Health. 2021 Jun 9;9:670941. doi: 10.3389/fpubh.2021.670941. eCollection 2021.
5
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌（艰难梭菌）。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
6
Fecal microbiota live - jslm (Rebyota™/RBL) for management of recurrent infection.用于治疗复发性感染的粪便微生物群活菌制剂-jslm（Rebyota™/RBL）
Future Microbiol. 2024;19(14):1243-1251. doi: 10.1080/17460913.2024.2364583. Epub 2024 Jul 11.
7
Butyrate Differentiates Permissiveness to Clostridioides difficile Infection and Influences Growth of Diverse C. difficile Isolates.丁酸盐可区分艰难梭菌感染的易感性，并影响不同艰难梭菌分离株的生长。
Infect Immun. 2023 Feb 16;91(2):e0057022. doi: 10.1128/iai.00570-22. Epub 2023 Jan 24.
8
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.复发性艰难梭菌感染：当前的临床管理及基于微生物群的治疗方法
BioDrugs. 2023 Nov;37(6):757-773. doi: 10.1007/s40259-023-00617-2. Epub 2023 Jul 26.
9
Microbiome therapeutics for the treatment of recurrent infection.用于治疗复发性感染的微生物组疗法。
Expert Opin Biol Ther. 2023 Jan;23(1):89-101. doi: 10.1080/14712598.2022.2154600. Epub 2022 Dec 19.
10
Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection.艰难梭菌感染患者口服冻干粪便微生物群移植后的长期细菌和真菌动态变化
mSystems. 2021 Feb 2;6(1):e00905-20. doi: 10.1128/mSystems.00905-20.
本文引用的文献
1
SER-109, an Oral Microbiome Therapy for Recurrent Infection.SER-109，一种用于复发性感染的口腔微生物组疗法。
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
2
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.美国传染病学会 (IDSA) 和美国医疗保健流行病学学会 (SHEA) 的临床实践指南：2021 年关于成人艰难梭菌感染管理的重点更新指南。
Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044. doi: 10.1093/cid/ciab549.
3
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!每日更进一步：恢复艰难梭菌复发的微生物群！
J Intern Med. 2021 Aug;290(2):294-309. doi: 10.1111/joim.13290. Epub 2021 Apr 15.
4
First clinical proof-of-concept that FMT can overcome resistance to ICIs.首次有临床概念验证表明粪菌移植（FMT）可克服对免疫检查点抑制剂（ICIs）的耐药性。
Nat Rev Clin Oncol. 2021 Jun;18(6):325-326. doi: 10.1038/s41571-021-00502-3.
5
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.RBX7455，一种非冷冻、口服的研究性活体生物治疗药物，在复发性艰难梭菌感染的 1 期研究中安全、有效，并能改变患者的微生物组。
Clin Infect Dis. 2021 Oct 5;73(7):e1613-e1620. doi: 10.1093/cid/ciaa1430.
6
Fecal microbiota transplantation for treatment of patients with recurrent infection.粪便微生物群移植治疗复发性感染患者。
Expert Rev Anti Infect Ther. 2020 Jul;18(7):669-676. doi: 10.1080/14787210.2020.1752192. Epub 2020 Apr 12.
7
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.SER-109，一种用于减少艰难梭菌感染后复发的研究性微生物组药物：来自 2 期试验的经验教训。
Clin Infect Dis. 2021 Jun 15;72(12):2132-2140. doi: 10.1093/cid/ciaa387.
8
Evolving Strategies to Manage Clostridium difficile Colitis.不断发展的艰难梭菌相关性结肠炎治疗策略。
J Gastrointest Surg. 2020 Feb;24(2):484-491. doi: 10.1007/s11605-019-04478-5. Epub 2019 Nov 25.
9
Oral microbiome: Unveiling the fundamentals.口腔微生物群：揭示基本原理。
J Oral Maxillofac Pathol. 2019 Jan-Apr;23(1):122-128. doi: 10.4103/jomfp.JOMFP_304_18.
10
Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic.RBX2660（一种研究性微生物群恢复疗法）2期试验中治疗反应者的细菌微生物群组成和多样性恢复
Open Forum Infect Dis. 2019 Apr 11;6(4):ofz095. doi: 10.1093/ofid/ofz095. eCollection 2019 Apr.
Zotero 插件